Role of Anti-VEGF (Bevacizumab) in Management of Neovascular Glaucoma: A Review
Abdulrahman Arshed N. Alharfy *
Tabuk University, Saudi Arabia.
Marwan Saleh D. Albalawi
Tabuk University, Saudi Arabia.
Abdulmajeed Mousa Alzahrani
Tabuk University, Saudi Arabia.
Ruby Naif M. Alsubaie
Tabuk University, Saudi Arabia.
Amani Ahmad S. Albalawi
Tabuk University, Saudi Arabia.
Waad Ali Alkaabneh
Tabuk University, Saudi Arabia.
Abdullah Ibrahim Altidlawi
Tabuk University, Saudi Arabia.
Amal Nafea J. Alharbi
Tabuk University, Saudi Arabia.
Afnan Mohammed H. Almutairi
Tabuk University, Saudi Arabia.
Rola Ali S. Alotabi
Tabuk University, Saudi Arabia.
*Author to whom correspondence should be addressed.
Abstract
Neovascular glaucoma (NVG) is an aggressive type of glaucoma, which often results in poor visual outcomes. Antivascular endothelial growth factor is frequently used for various conditions in which VEGF release is induced in response to retinal ischemia. Bevacizumab is a humanized anti-VEGF monoclonal IgG1 antibody. The potential of antivascular endothelial growth factor (anti-VEGF) agents to modify the disease course of neovascular glaucoma (NVG) was recognized shortly after their use in the treatment of age-related macular degeneration was reported. These medications were noted to induce rapid regression of the anterior segment neovascularization that characterizes NVG. Several studies as well as extensive clinical experience have demonstrated a rapid regression of anterior segment neovascularization following the injection of anti-VEGF agents. This review aims to summarize current evidences regarding effectiveness of Bevacizumab in management of neovascular glaucoma.
Keywords: Anti-VEGF, Bevacizumab, neovascular glaucoma